A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
Phase 1 Recruiting
214 enrolled
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Phase 1/2 Recruiting
245 enrolled
FiREBOLT
Phase 1 Recruiting
241 enrolled
FRAmework-01
Phase 3 Recruiting
1,080 enrolled
TroFuse-022
Phase 3 Recruiting
770 enrolled
MAESTRA 2
Phase 3 Recruiting
466 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
TroFuse-021
Phase 3 Recruiting
900 enrolled
DENALI
Phase 2 Recruiting
310 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
45 enrolled
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Phase 1/2 Recruiting
350 enrolled
A Study of XMT-1660 in Participants With Solid Tumors
Phase 1 Recruiting
319 enrolled
OCTOPOD
Phase 1/2 Recruiting
44 enrolled
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Phase 2 Recruiting
270 enrolled
MAESTRA 1
Phase 2 Recruiting
160 enrolled
ACTengine
Phase 1/2 Recruiting
375 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
MRD
Phase 1/2 Recruiting
30 enrolled
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 Recruiting
100 enrolled
OVATION-3
Phase 3 Recruiting
500 enrolled
SELECT-2CAR
Phase 1/2 Recruiting
72 enrolled
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Phase 2 Recruiting
200 enrolled
panSOHO
Phase 2 Recruiting
111 enrolled
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Phase 2 Recruiting
220 enrolled
RAINFOL-04
Phase 3 Recruiting
528 enrolled
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1 Recruiting
40 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
113 enrolled
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
386 enrolled
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 1 Recruiting
24 enrolled
INX-315-01
Phase 1/2 Recruiting
150 enrolled
MAIA-ovarian
Phase 1/2 Recruiting
60 enrolled
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Phase 1 Recruiting
24 enrolled
DP-04
Recruiting
100 enrolled
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Phase 1 Recruiting
187 enrolled
RAD301
Phase 1 Recruiting
9 enrolled
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
Phase 1 Recruiting
8 enrolled
ERADIC8
Phase 1/2 Recruiting
120 enrolled
BetaBart
Phase 1/2 Recruiting
61 enrolled
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Phase 1 Recruiting
226 enrolled
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
Phase 1 Recruiting
70 enrolled
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Phase 2 Recruiting
100 enrolled
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Phase 1 Recruiting
138 enrolled
NEXUS-01
Phase 1 Recruiting
420 enrolled
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Phase 1/2 Recruiting
460 enrolled
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Phase 1 Recruiting
280 enrolled
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Phase 1/2 Recruiting
205 enrolled
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Phase 2 Recruiting
454 enrolled
OLIVIA
Recruiting
250 enrolled